Dermatology Research
An Intervention Study for Adults with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
This study is currently closed to enrollment.
Proof-of-Activity Study with Orticumab in Subjects with Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
AGE: 30 years and older
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Plaque psoriasis
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: University Hospitals Cleveland Medical Center
LOCATION: University Hospitals Cleveland Medical Center
Study Purpose
The purpose of this research study is to test an experimental drug called Orticumab, a monocolonal antibody, to assess the safety and tolerability in subjects with moderate-to-severe psoriasis and cardiometabolic risk factors (obesity, high low-density lipoprotein (also called “LDL” or “bad” cholesterol), high blood fat (triglycerides), low high-density lipoprotein (also called “HDL” or “good” cholesterol), high blood pressure, diabetes, smoking tobacco).
STUDY ID#
- STUDY20210910